SOLVING CKD

Protecting against obesity-induced chronic kidney disease using pro-resolving lipids

Coordinatore	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN    more  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: +353 1 716 1656 Fax: +353 1 716 1216
Nazionalità Coordinatore	Ireland [IE]
Totale costo	267˙726 €
EC contributo	267˙726 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-IOF
Funding Scheme	MC-IOF
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-07-01   -   2015-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: +353 1 716 1656 Fax: +353 1 716 1216	IE (DUBLIN)	coordinator	267˙726.90

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'This project will explore the therapeutic potential of pro-resolving lipids in obesity-induced chronic kidney disease (CKD). The experienced researcher is Dr. Emma Börgeson and the mentors are Prof. Kumar Sharma (outgoing, University of California San Diego, USA) and Prof. Catherine Godson (return, University College Dublin, Ireland).

‘The epidemic of obesity poses one of the most serious public health challenges in the WHO European Region’ (WHO, 2006). Obesity is associated with chronic systemic low-grade inflammation. Failure to resolve this inflammation leads to development of associated complications such as CKD. The resolution of inflammation is actively regulated by endogenous pro-resolving lipid mediators, e.g. lipoxins (LXs) and resolvins (Rvs).

We hypothesise that 1) Pro-resolving lipids prevent obesity-induced adipose inflammation and thereby subvert kidney disease, 2) Humans developing obesity-related pathologies have impaired endogenous production of pro-resolving lipids. To investigate this we will assess the protective effects of pro-resolving lipids in animal models of obesity-induced kidney disease and elucidate the cellular signalling pathways involved (outgoing phase). We will correlate our findings to human obesity and investigate if development of obesity-related pathologies reflects an impairment of endogenous production of LXs and Rvs (return phase).

The synergy between Prof Sharma (expertise; obesity, CKD) and Prof Godson (expertise; inflammation, CKD) will provide a unique research opportunity to combine state of the art facilities and innovative research methodology. Dr. Börgeson will acquire significant technical skills, an international network as well as management, teaching and outreach experience. The fellowship will enhance her ability to secure a future career in European biomedical research.'

Introduzione (Teaser)

European researchers are working on a novel approach to treat obesity-related kidney problems. Their strategy entails the use of specific lipids that counteract inflammation